CFDE Data Portal | Search H3C9P

	Label	Description
	H3C9P Gene (Entity type)	ENSG00000220875 - H3 clustered histone 9, pseudogene
	GSE111247 temozolomide LN-308 14 v 12 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE195568 palbociclib 1 v 10 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE152699 GSE152723 vemurafenib 3 v 1 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE176008 pyridoxine 0 v 1 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE111247 temozolomide LN-308 14 v 6 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE233112 doxorubicin 2 v 0 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE111247 temozolomide LN-308 2 v 4 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE151090 verteporfin 0 v 3 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE236228 penfluridol 0 v 1 human dn Gene Set (Entity type)	A Gene Set from LINCS

H3C9P

ENSG00000220875 - H3 clustered histone 9, pseudogene

GSE111247 temozolomide LN-308 14 v 12 human dn

A Gene Set from LINCS

GSE195568 palbociclib 1 v 10 human up

A Gene Set from LINCS

GSE152699 GSE152723 vemurafenib 3 v 1 human up

A Gene Set from LINCS

GSE176008 pyridoxine 0 v 1 human dn

A Gene Set from LINCS

GSE111247 temozolomide LN-308 14 v 6 human dn

A Gene Set from LINCS

GSE233112 doxorubicin 2 v 0 human dn

A Gene Set from LINCS

GSE111247 temozolomide LN-308 2 v 4 human dn

A Gene Set from LINCS

GSE151090 verteporfin 0 v 3 human up

A Gene Set from LINCS

GSE236228 penfluridol 0 v 1 human dn

A Gene Set from LINCS

DISPLAY PER PAGE

@CFDE Workbench 2026

The CFDE Workbench is actively being developed and maintained by the CFDE Data Resource Center (DRC).The DRC is funded by OT2OD036435 from the Common Fund at the National Institutes of Health.

The CFDE Workbench is actively being developed and maintained by the CFDE Data Resource Center (DRC).The DRC is funded by OT2OD036435 from the Common Fund at the National Institutes of Health.

@CFDE Workbench 2026

This repository is under review for potential modification in compliance with Administration directives.